A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy And Safety of Belimumab Administered Subcutaneously in Adults With Systemic Sclerosis Associated Interstitial Lung Disease (SSC-ILD)

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belimumab (Primary)
Indications Interstitial lung diseases; Systemic scleroderma
Focus Registrational; Therapeutic Use
Acronyms BLISSc-ILD
Sponsors GlaxoSmithKline; GSK

Most Recent Events

03 Mar 2025 Planned primary completion date changed from 12 Jul 2027 to 17 May 2027.
24 Oct 2024 Planned End Date changed from 15 Feb 2027 to 12 Jul 2027.
24 Oct 2024 Planned primary completion date changed from 15 Feb 2027 to 12 Jul 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight